rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PALI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Palisade Bio Analysts Slash Their Forecasts After Q3 Results
      Nov 11BenzingaPALI
      Palisade Bio doses first patient in ulcerative colitis trial
      Nov 10Investing.comPALI
      Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
      Nov 10Yahoo FinancePALI
      Palisade: Initiating 'Buy' On PALI-2108 UC Study Start And Differentiated PDE4 Inhibitor

      Palisade Bio's phase 2b ASCENTRA-UC trial for ulcerative colitis has begun dosing, with 12-week topline results expected in Q4 2027. I rate PALI stock as Buy.

      Nov 2Seeking AlphaPALI
      Palisade Bio doses first patient in ulcerative colitis trial
      Oct 28Investing.comPALI
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

      Oct 24The Globe and MailPALIRLAY
      Oppenheimer Remains a Buy on Palisade Bio (PALI)

      Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.

      Oct 22The Globe and MailPALI
      Oppenheimer reiterates Palisade Bio stock rating on Crohn’s data
      Oct 21Investing.comPALI
      Palisade Bio reports early-stage Crohn’s disease trial results
      Oct 20Investing.comPALI
      H.C. Wainwright reiterates Palisade Bio stock rating at buy
      Oct 13Investing.comPALI
      Palisade Bio presents clinical data on ulcerative colitis drug
      Oct 12Investing.comPALI
      Palisade Bio director buys $28,800 in PALI stock
      Oct 12Investing.comPALI
      Raymond James Initiates Palisade Bio at Outperform With $6 Price Target
      Oct 9Yahoo FinancePALI
      Palisade Bio stock initiated at Outperform by Raymond James
      Oct 8Investing.comPALIRJF
      Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s

      Palisade Bio (NASDAQ:PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn’s disease after completing its Phase I program. Chief Executive Officer JD Finley said PALI-2108 is a once-daily oral phosphodiesterase 4, or PDE4, inhibitor de

      Sep 27Yahoo FinancePALI
      Palisade Bio Gets Clearance for Phase 2 Trial of Ulcerative Colitis Treatment in Canada

      Palisade Bio (PALI) has obtained clearance from Health Canada for its global phase 2 study evaluatin

      Sep 23Yahoo FinancePALI
      Palisade Bio receives Health Canada clearance for UC trial
      Sep 23Investing.comPALI
      Palisade Bio Gets FDA Clearance for PALI-2108 in Crohn's Disease

      Palisade Bio (PALI) said the US Food and Drug Administration cleared its investigational new drug ap

      Sep 22Yahoo FinancePALI
      Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD

      ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s diseaseFirst patient dosing targeted for Q1 2027; primary...

      Sep 22Business InsiderPALI
      FDA clears Palisade Bio’s phase 2 trial for Crohn’s disease drug
      Sep 22Investing.comPALI
      Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

      Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that JD Finley, Chief Executive Officer, and Mitchell Jones, M.D., Ph.D., President and Chief Medical Officer, will participate in the Stifel 2026 V

      Sep 21Yahoo FinancePALI
      Palisade Bio at H.C. Wainwright conference: IBD drug push
      Sep 16Investing.comPALI
      Palisade Bio at Morgan Stanley conference: broadens ibd push
      Sep 16Investing.comPALIMS
      Palisade Bio to Participate in Upcoming Investor Conferences

      Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that members of management will participate in three healthcare investor conferences in September 2026. Wells Fargo 2026 Healthcare Conference Dates: September 8–10, 2026Location: Boston, MassachusettsFormat: Investor meetings Morga

      Sep 3Yahoo FinancePALI

      This is the newest page. Registered accounts read further back.